Abstract. Lung cancer is the leading cause of cancer-associated mortality, worldwide. For this reason, novel therapies are required for the treatment of this devastating disease. Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR), which is overexpressed in a variety of solid tumors, including non-small cell lung cancer (NSCLC). The therapeutic efficacy of cetuximab for NSCLC is limited to use as a monotherapy or in combination with chemotherapy. The objective of the present study was to develop a novel strategy to enhance the therapeutic efficacy of cetuximab for NSCLC by a co-administration with the tumor-penetrating internalizing RGD peptide (iRGD). Human NSCLC subcutaneous xenograft models established with the A549 cell line in nude mice were treated with 30 mg/kg cetuximab, 4 mg/kg iRGD, cetuximab plus iRGD or phosphate-buffered saline. The tumor-penetration, in vivo therapeutic efficacy and involved mechanism were evaluated. The present study showed that the A549 xenograft model is sensitive to the co-administration of cetuximab and iRGD. Treatment with cetuximab plus iRGD resulted in a significant increase in the tumor-penetration of cetuximab and tumor reduction compared with cetuximab monotherapy. In conclusion, iRGD enhances the effects of co-administered cetuximab in an NSCLC model. The combined application of cetuximab and iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of cetuximab for the treatment of NSCLC.
Introduction
Lung cancer is one of the most common malignant tumors to occur, worldwide. The two major subtypes are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (1) . NSCLC accounts for ~85% of all lung cancer cases (2) . For early-stage or locally advanced lung cancer, surgery is the most effective treatment and combined chemotherapy is the standard adjuvant approach. However, ~40% of patients with NSCLC present with unresectable, metastatic stage IV tumors (3) . The prognosis is poor, and the overall 5-year survival rate remains <15% (2) . Since the effectiveness of current standard treatment for advanced NSCLC (i.e. chemotherapy) has reached a ceiling (4) , there is a continuous requirement for novel, more effective treatments to further improve the outcome of patients with the disease.
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that is overexpressed in numerous solid tumors, including NSCLC (5) . The binding of a ligand, for example transforming growth factor-α or epidermal growth factor, to EGFR triggers tyrosine kinase phosphorylation, which in turn activates cellular pathways, including the mitogen-activated protein kinase, phosphatidylinositol 3' kinase and protein kinase B pathways. The ultimate result is cell growth and tumor progression. Therefore, EGFR is an important therapeutic target in NSCLC (6) .
Cetuximab (Erbitux ® ) is a chimeric human-murine monoclonal immunoglobulin (Ig)G1 antibody. It blocks ligand binding to EGFR, leading to a decrease in receptor dimerisation, autophosphorylation and activation of signaling pathways (7) . Cetuximab may also act by means Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (2) . In 2004, the results of a single-agent phase II study of cetuximab in recurrent NSCLC were reported, with 29 EGFR-positive patients showing a partial response rate of 7% and a stable disease rate of 17% (8) . Two randomized phase III trials that evaluated cetuximab in NSCLC patients showed a small benefit in terms of overall survival for the experimental treatment, which was considered insufficient by the European Medicines Agency for marketing approval (1) . One of the possible reasons for limited therapeutic efficacy of cetuximab in NSCLC may be that the increased interstitial fluid pressure inside the tumor prevents the antibody from being delivered into the extravascular tumor tissue (9) (10) (11) (12) . The tumor-targeted delivery of anticancer agents is considered as a novel strategy to traditional chemotherapy. Tumor-targeted delivery has been proved to selectively increase the drug concentration at the tumor site and significantly improve the therapeutic efficacy (13) . Previously, a tumor-penetrating internalizing RGD peptide (iRGD; amino acid sequence, CRGDK/RGPD/EC), was identified and reported to increase vascular and tissue penetration in a tumor-specific and neuropilin-1 (NRP-1)-dependent manner (14) . The RGD tripeptide of iRGD can bind the αvβ3 and αvβ5 integrins, the expression of which is largely restricted to tumors, including tumor vasculature and cells (14, 15) . When iRGD binds to integrins, the peptide bond between the K and G amino acids is proteolytically cleaved by the cell surface-associated proteases to expose the cryptic C-end rule (CendR) motif (amino acid sequence, CRGDK/R), which then binds to NRP-1 (14) (15) (16) (17) . The activation of NRP-1 increases the permeability of blood vessels and tumor tissues, which allows drugs to penetrate into the internal tissue of the tumor much more easily (14, 15, 18) . Thus, when anticancer agents are modified with iRGD, the tissue-penetrating and tumor-targeting properties can be improved. Additionally, when iRGD was previously co-administered with drugs or a systemic injection drug delivery system, antitumor activities were also improved (18) .
The characteristics of iRGD in solid cancers appear to warrant further investigation; particularly, for patients with diseases that have a dismal prognosis, such as NSCLC. However, there have been no comprehensive in vivo studies using NSCLC models, and the effects of iRGD used in combination with cetuximab have not yet been tested. Therefore, the present study examined the effectiveness of iRGD for boosting cetuximab accumulation in NSCLC xenograft models established with the A549 cell line. The anticancer booster effect of combination therapy with cetuximab plus iRGD was evaluated with in vivo experiments.
Materials and methods
Cell culture. The human NSCLC-derived A549 cell line was purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China), and cultured in F-12K medium with 10% fetal bovine serum and 1% penicillin/streptomycin (all Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cells were cultured in a humidified atmosphere containing 5% CO 2 at 37˚C. Mice and in vivo experiments. In vivo experiments involved 69 six-week-old female BALB/C nude mice (Vital River Laboratory Animal Technology Co., Ltd, Beijing, China), which were housed in the specific pathogen-free animal facility of Experimental Animal Center, Xuzhou Medical College (Xuzhou, China). Animals were housed with a 12-h light/dark cycle, at 22±1˚C, and in a 55±5% humidity-controlled room. All mice were allowed free access to clean water and food. All cages housed up to 6 animals and contained wood shavings and an independent air supply system. All animal experimental protocols were approved and reviewed by the Institutional Animal Care and Use Committee of the Jiangsu Provincial Academy of Chinese Medicine (approval no., SCXK 2012-0005). During in vivo experiments, animals in all experimental groups were examined daily for physical activity. At the end of the experiment, mice were sacrificed by cervical dislocation.
Tumor model. The human NSCLC model was established as previously described (19) . Briefly, 1x10 7 A549 cells were injected into the left forelimb armpits of 6 BALB/c nude mice. When the tumors grew to ~150 mm 3 , the mice were sacrificed by cervical dislocation, and the tumors were harvested and segmented into tissue blocks (4-6 mm 3 in size). Subsequently, the left forelimb armpits of three BALB/c nude mice were inoculated subcutaneously with the tissue blocks using a trocar. The mice were sacrificed when the tumors grew to the desired size.
Immunofluorescence staining. Three mice were used to establish human NSCLC models. When the tumors reached ~200 mm 3 , the mice were sacrificed and the tumors were dissected and sectioned on a cryostat. For αvβ3, αvβ5 and NRP-1 detection, the sections (n=3) were incubated overnight at 4˚C with the same anti-human αvβ3, αvβ5 and NRP-1, or isotype control antibodies, as those used in the flow cytometry analysis. After washing, all sections were observed and photographed with a fluorescence microscope (DS-Ri1; Nikon Corporation, Toyko, Japan).
Tumor permeability assay. When tumors reached ~200 mm 3 , the mice were divided into 4 groups (n=9/group). A total of 30 mg/kg cetuximab (Merck Millipore, Darmstadt, Germany), 4 mg/kg iRGD (Shanghai Apeptide Co., Ltd., Shanghai, China), 30 mg/kg cetuximab+4 mg/kg iRGD or PBS was injected into each of the 4 groups of tumor-bearing mice via the tail vein. After 1, 3 and 9 h, 3 mice per group were anesthetized by intraperitoneal injection with 3.5% chloral hydrate (0.2 ml/mouse; Shanghai Shifeng Biological Technology, Co., Ltd., Shanghai, China). After 2 min, the mice were perfused through the heart with PBS containing 1% bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA). The tumors were then collected and sectioned on a cryostat. The tumor vasculature marker cluster of differentiation (CD)31 was stained with a rabbit anti-mouse CD31 polyclonal antibody (cat. no. ab28364; Abcam, Cambridge, MA, USA) and a DyLight 549-conjugated goat anti-rabbit IgG (H+L) secondary antibody (cat. no. E032320; EarthOx Life Sciences, Millbrae, CA, USA) was used for visualization. Cetuximab was stained with the DyLight 488-conjugated goat anti-human IgG (H+L) antibody (cat. no. 109-485-003; Jackson ImmunoResearch Inc., West Grove, PA, USA). The nuclei were stained with 4',6-diamidino-2-phenylindole (Roche Diagnostics GmbH, Mannheim, Germany). Imaging was performed using a confocal microscope (OLS4100; Olympus Corporation, Tokyo, Japan). At least 5 random visual areas were chosen in every slide. The percentage and the integrated optical density (IOD) index of positively stained regions were scanned and analyzed using Image-Pro Plus (IPP) 6.0 software (Media Cybernetics Inc., Rockville, MD, USA). The penetration distance between the vessel and where the fluorescence decreased to background levels was also analyzed using the IPP software.
In vivo efficacy studies. When the tumors reached ~100 mm 3 , the mice were divided into 4 groups (n=6/group). The same injections as described for the tumor permeability assay were performed twice a week for a total of 8 times. The volume of the tumors was measured in two perpendicular directions with a caliper, and the weight of the mice was calculated every 3 days. The volume of the tumor was measured using the following formula: V=0.5x(W 2 xL); where V=tumor volume, W=the smaller perpendicular diameter and L=the larger perpendicular diameter. On day 30 following the first injection, the mice were sacrificed and the tumors were collected and weighed. The tumor growth inhibition ratio (TGIR) was calculated using the formula: TGIR=(W-W t )/Wx100; where W is the average tumor weight of the PBS group and W t is the average tumor weight of the treatment group. Each tumor was cut into two equal parts: one part was fixed in 10% neutral-buffered formalin for immunohistochemical staining and the TdT-mediated dUTP nick end labeling (TUNEL) assay; and the other part was snap-frozen in liquid nitrogen for western blot analysis.
Immunohistochemical staining. The fixed tumor tissues were embedded in paraffin and cut into 3-5 µm sections (20) . The experiment was performed on with a streptavidin-peroxidase system (OriGene Technologies, Inc., Beijing, China). EGFR and phosphorylated EGFR (p-EGFR) were detected with a rabbit anti-human EGFR antibody (cat. no. ab52894; Abcam) and a rabbit anti-human p-EGFR antibody (cat. no. 36-9700; Thermo Fisher Scientific, Inc.), respectively. Imaging was performed by fluorescence microscopy (DS-Ri1; Nikon Corporation). To determine the IOD indices of EGFR and p-EGFR, 5 representative visual areas that were positive for EGFR or p-EGFR were examined from each tumor. The EGFR and p-EGFR indices for each selected area were analyzed using IPP 6.0 software.
Western blot analysis. Total protein was extracted using radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Nanjing, China) containing 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich). Protein lysates were separated by 10% SDS-PAGE, followed by transfer to polyvinylidene difluoride membranes. The membranes were blocked with PBS containing 0.01% Tween-20 (PBST) and 5% (w/v) fat-free dried milk for 1 h, followed by incubation with anti-EGFR and anti-p-EGFR antibodies (see above), and rabbit anti-β-actin polyclonal antibody (cat. no. ab8227; Abcam) for 1 h. Subsequently, the membranes were washed five times with PBST and incubated with IRDye 800CW goat anti-rabbit IgG (H+L) antibody (cat. no. 926-32211; LI-COR Biosciences, Lincoln, NE, USA) for 1 h. β-actin was detected as an internal control. After washing the membranes another five times with PBST, images were captured using an Odyssey enhanced chemiluminescence system (LI-COR Biosciences) and the intensity of the bands was quantified by ImageJ2x 2.1.4.7 software (Rawak Software, Inc., Stuttgart, Germany).
TUNEL assay. The paraffin sections were prepared, as described in the immunohistochemical staining section. The apoptotic cells were detected using a TUNEL assay kit (cat. no. 1684809; Roche Diagnostics), according to the manufacturer's protocol. Imaging was performed by fluorescence microscopy (DS-Ri1). The number of TUNEL-positive cells in 5 randomly selected fields from each tumor was counted. The percent of TUNEL-positive cells was calculated as the apoptotic index. A total of 100 cells were randomly selected for each field.
Statistical analysis. SPSS version 16.0 for Windows (SPSS, Inc., Chicago, IL, USA) was used for all analyses. Quantitative data were presented as the mean ± standard deviation. Comparisons between two groups were performed using independent-sample Student's t-tests, while multiple samples were compared with one-way analysis of variance, with α=0.05 as a level for the test. Results with a P-value of <0.05 were considered to indicate a statistically significant difference.
Results

Expression of ανβ3, ανβ5, NRP-1 and EGFR in A549 cells and xenograft tissue.
The tumor-penetrating ability of iRGD mainly depends on the level of ανβ3, ανβ5 and NRP-1 in cancer cells (18, 21) . The therapeutic efficacy of cetuximab mainly depends on the level of EGFR in cancer cells (22) .
In order to confirm the expression of these molecules in the human NSCLC A549 cell line, a flow cytometry analysis was performed. As shown in Fig. 1A , the positive expression rates of αvβ3, αvβ5, NRP-1 and EGFR were 65.1, 32.0, 88.8 and 96.3%, respectively. This result demonstrated that the A549 cell line may be used to establish a human NSCLC model for the study of the combination therapy of cetuximab and iRGD. To confirm the level of αvβ3, αvβ5, and NRP-1 in tumor tissue, a BALB/c nude mouse xenograft model was developed with the A549 cell line. The expression of these molecules in tumor tissue was additionally detected by immunofluorescence staining. As shown in Fig. 1B, αvβ3 (left), αvβ5 (middle) and NRP-1 (right) were overexpressed in the xenograft tissues.
Tumor-penetrating ability of cetuximab combined with iRGD.
To determine whether iRGD can promote the penetration of cetuximab into the human NSCLC xenograft, cetuximab that penetrated into the tumor tissue was detected by immunofluorescence staining. As shown in Fig. 2A , much more cetuximab could be observed in the cetuximab+iRGD group compared with in the cetuximab group, particularly after 3 and 9 h (Fig. 2A) . The results of the quantitative analysis showed that the penetrating depths of cetuximab into the tumors in the cetuximab+iRGD group were 2.0, 2.3 and 2.0 times the cetuximab only group; that the diffusing areas were 3.2, 3.5 and 2.4 times the cetuximab only group; and the accumulated amounts were 2.9, 3.8 and 4.1 times the cetuximab only group at 1, 3 and 9 h of treatment, respectively (Fig. 2B ). These differences were statistically significant.
Therapeutic efficacy of cetuximab co-administered with iRGD.
In order to determine an appropriate dose, at which cetuximab efficiently inhibits tumor growth without evident side effects, 3 doses of cetuximab (10, 30 and 90 mg/kg) were applied to treat 3 groups of mice (n=3) via tail vain, twice per week for two consecutive weeks. After two weeks, the mice in that 10 and 30 mg/kg groups appeared normal, but the mice in the 90 mg/kg group showed an apparent lack of energy and loss of appetite. According to a previous study, the A549 xenograft in mice is sensitive to cetuximab at doses of 4 mg/kg and 40 mg/kg (22) . Taking the efficacy and side effects into consideration, the present study chose 30 mg/kg as the dose of cetuximab in the in vivo therapeutic efficacy experiments.
To determine whether the therapeutic efficacy of cetuximab is enhanced when it is co-administered with iRGD, cetuximab and iRGD were co-administered to treat the mice with A549 xenografts. As shown in Fig. 3A , the tumors of the cetuximab+iRGD 
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group grew more slowly compared with the tumors in the cetuximab group, and this difference was statistically significant. The analysis of average tumor weight further confirmed this result (Fig. 3B) . These results demonstrated that iRGD could enhance the therapeutic efficacy of cetuximab for A549 xenografts in mice. The body weight shift analysis of the experimental mice showed that no significant difference was observed between the cetuximab group and the cetuximab+iRGD group (Fig. 3C) . These results demonstrated that iRGD did not evidently exacerbate the side effects of cetuximab.
EGFR phosphorylation in the tumors treated with cetuximab plus iRGD.
With regards to the aforementioned results, iRGD promoted the penetration of cetuximab into tumor tissue and enhanced the therapeutic efficacy of cetuximab for the A549 xenograft. Therefore, theoretically, the co-administration of cetuximab and iRGD could result in the increased inhibition of EGFR phosphorylation compared with cetuximab monotherapy. In order to confirm this speculation, the present study first detected the phosphorylation level of EGFR in the tumor tissues by immunohistochemical staining. The expression Fig. 4A and B) ; however, the phosphorylation of EGFR in the cetuximab+iRGD group was reduced by 57.1% compared with the cetuximab group, which was statistically significant ( Fig. 4A and C) . To further confirm the expression level of EGFR and p-EGFR, the total proteins were extracted from the tumor tissues in each group. The expression levels of EGFR and p-EGFR were detected by western blot analysis with β-actin as an internal control. Each strip was scanned and a quantitative analysis was performed with ImageJ software. The expression level of EGFR in the tumor tissues of the 4 groups had no significant difference (Fig. 4D and E) ; however, the expression level of p-EGFR in the cetuximab+iRGD group was reduced by 82.6% compared with the cetuximab group (Fig. 4D and F) . Overall, these results confirmed that the therapeutic efficacy of cetuximab was enhanced when used in combination with the tumor-penetrating peptide iRGD.
Induction of apoptosis in the tumors treated with cetuximab plus iRGD.
Previous studies have shown that cetuximab can induce cancer cell apoptosis by competitively blocking the binding of EGFR to its natural ligands (9, 23) . Therefore, the present study detected the apoptosis of the cancer cells in the mice treated with A549 xenografts using a TUNEL assay. As shown in Fig. 5A , more apoptotic cells were visible in tumors of the cetuximab+iRGD group compared with tumors of the cetuximab group. The apoptotic index was defined as the percentage of TUNEL-positive cells vs. the total number of cells. According to the statistical analysis shown in Fig. 5B , the rate of apoptosis in tumors of the cetuximab+iRGD group was 2.1 times the apoptosis rate in tumors of the cetuximab group. These results further confirmed that iRGD enhanced the therapeutic efficacy of cetuximab in the human NSCLC xenograft.
Discussion
The present study was conducted to evaluate the use of iRGD for co-administration therapy with cetuximab, and demonstrated that iRGD boosted the accumulation of cetuximab in human NSCLC xenograft models established with the A549 cell line. The anticancer effects of cetuximab were also enhanced by iRGD co-administration in this NSCLC model. To further verify the effects of drug accumulation and anticancer, the phosphorylation of EGFR and cell apoptosis were detected in the treated tumors.
The experiments using A549 xenograft models confirmed the enhanced cetuximab accumulation effect and therapeutic efficacy of iRGD. Previous reports demonstrated that the drug accumulation effect of iRGD is dependent on the level The results of the present study showed that these molecules are overexpressed in A549 cells and in the xenograft tissue. Furthermore, cetuximab accumulation was detected in tumor tissues. The results showed that the accumulation of cetuximab in tumor tissue is enhanced by iRGD. Theoretically, the enhanced accumulation of cetuximab in tumor tissues could result in decreased EGFR phosphorylation, increased cell apoptosis and inhibited tumor growth. The results of the current study were consistent with these theoretical speculations. Therefore, the results confirmed that iRGD can enhance the tumor-penetration and therapeutic efficacy of cetuximab in A549 xenograft models. It is possible that combination with iRGD enhances the therapeutic efficacy and decreases the side effects of cetuximab. The results of a single-agent, phase II study in recurrent NSCLC (n=29) showed limited therapeutic efficacy; 7% of patients showed a partial response and 17% patients showed stable disease (8) . In one phase III trial, cetuximab was evaluated in combination with docetaxel and pemetrexed in patients with advanced NSCLC, and the results indicated that cetuximab does not add any benefit to second line chemotherapy for patients with NSCLC (25, 26) . The BMS099 trial also failed to show a significant improvement in progression-free survival (5) . In the present study, iRGD was combined with cetuximab to treat an NSCLC xenograft model, and the results indicated that iRGD can enhance the therapeutic efficacy of cetuximab for NSCLC without evident side effects at dose of 30 mg/kg. Therefore, it is possible that iRGD may add benefit to cetuximab for patients with NSCLC. However, the efficacy of iRGD has only been examined in the A549 cell line, so the clinical applications of these findings require careful consideration.
The use of cetuximab and iRGD combination therapy may have certain problems if it is applied clinically. The current understanding of the mechanism by which iRGD enhances the therapeutic efficacy of cetuximab for NSCLC is limited. Although no evident side effects were observed in the present study, the safety of this combination therapy requires additional evaluation. The CendR motif of iRGD may also be used by viruses and microbial toxins in order to gain entry into cells and spread within the tissues of the body (27) (28) (29) . Since EGFR is also overexpressed in novel vessels, iRGD also may promote the uptake of cetuximab into normal tissues that are damaged, and the tissue repair that follows may interfere with the normal function of EGFR and cause further damage to the body.
In summary, through a human NSCLC A549 nude mouse xenograft model, iRGD was confirmed to promote the penetration of cetuximab into tumor tissue and therefore enhance the therapeutic efficacy of cetuximab in vivo. The combined application of cetuximab and iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of cetuximab for the treatment of NSCLC. A B
